Real-World Effectiveness of Biologic Agents Used to Treat Moderate-to-Severe Plaque Psoriasis in Poland: Between Treatment Comparison

OBJECTIVES: The objective of this study was to compare the real-world effectiveness of biologic agents used in treating moderate-to-severe plaque psoriasis in Poland.

METHODS: The analysis of treatment effectiveness was conducted using data from approximately 5,000 patients with moderate-to-severe plaque psoriasis treated with biologic agents, enrolled in . The dataset provides details about patients, including demographic information, previous therapies, and qualification dates. It also tracks checkpoint dates and types, patient weight, medications, and current health indices. Eleven biologic agents is available in the program , however one was removed from the analysis as too recently introduced. The Psoriasis Area and Severity Index (PASI) was used to assess the effectiveness of treatment, with PASI75, used as the primary measure of treatment efficacy. The percentage of patients achieving PASI75 was assessed between the 12^th and 16^th weeks, as well as between the 36^th and 40^th weeks of treatment.

RESULTS: Between 69% and 93% patients achieved PASI75 between the 12^th and 16^th weeks of treatment. The After 36 to 40 weeks of treatment, the effectiveness of all but two biologic agents increased, with the percentage of patients reaching PASI75 ranging between 70 and 100.

CONCLUSIONS: ologic agents demonstrated high real-world effectiveness in PASI reduction in patients with moderate-to-severe plaque psoriasis in Poland. The effectiveness of the treatment was relatively stable between the 12^th and 40^th week of treatment.